Lorlatinib was first studied in an international, multicentre, single-arm first-in-man phase 1 trial that showed its systemic and intracranial activity in patients with ALK- or ROS1-rearranged NSCLC, previously treated with ALK/ROS1 TKIs. This evidence concerns the gene ALK and non-small cell lung carcinoma.